Interim report January - September 2017
July – September 2017 · Net sales amounted to SEK 1,200 million (1,138), an increase of 5.5% · EBITDA amounted to SEK 103 million (144) corresponding to an EBITDA margin of 8.6% (12.6) · Operating profit (EBIT) amounted to SEK -17 million (44) · Profit after tax amounted to SEK -54 million (12) corresponding to a net margin of -4.5% (1.0) · Earnings per share amounted to SEK -0.89 (0.14) before dilution and SEK -0.89 (0.14) after dilution · Recipharm signed collaboration agreement with Roche January – September 2017 · Net sales amounted to SEK 3,